Reacts with external domain of EGF receptor on all human cells. Competes with EGF and TGF-a for binding on human cells.
Background Information
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα). Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. There is also evidence to suggest that clusters of activated EGFRs form, although it remains unclear whether this clustering is important for activation itself or occurs subsequent to activation of individual dimers.
EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of five tyrosine (Y) residues in the C-terminal domain of EGFR occurs. These are Y992, Y1045, Y1068, Y1148 and Y1173. This autophosphorylation elicits downstream activation and signaling by several other proteins that associate with the phosphorylated tyrosines through their own phosphotyrosine-binding SH2 domains. These downstream signaling proteins initiate several signal transduction cascades, principally the MAPK, Akt and JNK pathways, leading to DNA synthesis and cell proliferation. Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation. The kinase domain of EGFR can also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and can itself be activated in that manner.
Product Information
Format
Purified
Control
Positive Control Included: Non-Stim A431 Cell Lysate (12-301)
Presentation
Lyophilized protein G Purified mouse immunoglobulin. Lyophilized from 0.1M Tris-glycine, pH 7.4, 0.15M NaCl containing no preservatives.
Applications
Application
Detect EGFR using this Anti-EGFR Antibody, neutralizing, clone LA1 validated for use in IC, IP, NEUT & WB.
Key Applications
Immunocytochemistry
Western Blotting
Neutralizing
Immunoprecipitation
Biological Information
Immunogen
Human A431 membrane proteins.
Clone
LA1
Host
Mouse
Specificity
Recognizes both phosphorylated and non-phosphorylated human EGF receptors.
FUNCTION:SwissProt: P00533 # Isoform 2/truncated isoform may act as an antagonist. SIZE:1210 amino acids; 134277 Da SUBUNIT:Binds RIPK1. CBL interacts with the autophosphorylated C- terminal tail of the EGF receptor. Part of a complex with ERBB2 and either PIK3C2A or PIK3C2B. The autophosphorylated form interacts with PIK3C2B, maybe indirectly. Interacts with PELP1. SUBCELLULAR LOCATION:Cell membrane; Single-pass type I membrane protein. & Isoform 2: Secreted. TISSUE SPECIFICITY:Expressed in placenta. Isoform 2 is also expressed in ovarian cancers. PTM:Phosphorylation of Ser-695 is partial and occurs only if Thr- 693 is phosphorylated. & Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occur.DISEASE:SwissProt: P00533 # Defects in EGFR are associated with lung cancer [MIM:211980]. SIMILARITY:SwissProt: P00533 ## Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily. & Contains 1 protein kinase domain. MISCELLANEOUS:Binding of EGF to the receptor leads to dimerization, internalization of the EGF-receptor complex, induction of the tyrosine kinase activity, stimulation of cell DNA synthesis, and cell proliferation.
Product Usage Statements
Quality Assurance
routinely evaluated on RIPA lysates from non-stimulated human A431 cells
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Lyophilized: 2 years at -20°C; Rehydrated: 1 month at 4°C or 6 months at -20°C
Packaging Information
Material Size
250 µg
原厂资料：
Key Spec Table
Species Reactivity
Key Applications
Host
Format
Antibody Type
H
ICC, WB, NEUT, IP
M
Purified
Monoclonal Antibody
Description
Catalogue Number
05-101
Replaces
04-337; 04-338
Brand Family
Upstate
Trade Name
Upstate
Description
Anti-EGFR Antibody, neutralizing, clone LA1
Overview
Reacts with external domain of EGF receptor on all human cells. Competes with EGF and TGF-a for binding on human cells.
Background Information
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα). Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. There is also evidence to suggest that clusters of activated EGFRs form, although it remains unclear whether this clustering is important for activation itself or occurs subsequent to activation of individual dimers.
EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of five tyrosine (Y) residues in the C-terminal domain of EGFR occurs. These are Y992, Y1045, Y1068, Y1148 and Y1173. This autophosphorylation elicits downstream activation and signaling by several other proteins that associate with the phosphorylated tyrosines through their own phosphotyrosine-binding SH2 domains. These downstream signaling proteins initiate several signal transduction cascades, principally the MAPK, Akt and JNK pathways, leading to DNA synthesis and cell proliferation. Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation. The kinase domain of EGFR can also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and can itself be activated in that manner.
Product Information
Format
Purified
Control
Positive Control Included: Non-Stim A431 Cell Lysate (12-301)
Presentation
Lyophilized protein G Purified mouse immunoglobulin. Lyophilized from 0.1M Tris-glycine, pH 7.4, 0.15M NaCl containing no preservatives.
Applications
Application
Detect EGFR using this Anti-EGFR Antibody, neutralizing, clone LA1 validated for use in IC, IP, NEUT & WB.
Key Applications
Immunocytochemistry
Western Blotting
Neutralizing
Immunoprecipitation
Biological Information
Immunogen
Human A431 membrane proteins.
Clone
LA1
Host
Mouse
Specificity
Recognizes both phosphorylated and non-phosphorylated human EGF receptors.
FUNCTION:SwissProt: P00533 # Isoform 2/truncated isoform may act as an antagonist. SIZE:1210 amino acids; 134277 Da SUBUNIT:Binds RIPK1. CBL interacts with the autophosphorylated C- terminal tail of the EGF receptor. Part of a complex with ERBB2 and either PIK3C2A or PIK3C2B. The autophosphorylated form interacts with PIK3C2B, maybe indirectly. Interacts with PELP1. SUBCELLULAR LOCATION:Cell membrane; Single-pass type I membrane protein. & Isoform 2: Secreted. TISSUE SPECIFICITY:Expressed in placenta. Isoform 2 is also expressed in ovarian cancers. PTM:Phosphorylation of Ser-695 is partial and occurs only if Thr- 693 is phosphorylated. & Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occur.DISEASE:SwissProt: P00533 # Defects in EGFR are associated with lung cancer [MIM:211980]. SIMILARITY:SwissProt: P00533 ## Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily. & Contains 1 protein kinase domain. MISCELLANEOUS:Binding of EGF to the receptor leads to dimerization, internalization of the EGF-receptor complex, induction of the tyrosine kinase activity, stimulation of cell DNA synthesis, and cell proliferation.
Product Usage Statements
Quality Assurance
routinely evaluated on RIPA lysates from non-stimulated human A431 cells
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Lyophilized: 2 years at -20°C; Rehydrated: 1 month at 4°C or 6 months at -20°C
京公网安备11010802025653 版权所有：北京逸优科技有限公司
